AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 11.8% in January

AngioDynamics, Inc. (NASDAQ:ANGO) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 882,000 shares, a decrease of 11.8% from the December 31st total of 1,000,000 shares. Based on an average trading volume of 625,200 shares, the days-to-cover ratio is presently 1.4 days.

AngioDynamics Price Performance

AngioDynamics stock traded down $0.75 during trading hours on Friday, reaching $11.72. The company had a trading volume of 925,398 shares, compared to its average volume of 1,068,643. The company has a 50-day moving average price of $9.61 and a 200 day moving average price of $8.03. The firm has a market cap of $474.11 million, a price-to-earnings ratio of -2.08 and a beta of 0.59. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS. As a group, research analysts expect that AngioDynamics will post -0.37 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on ANGO shares. HC Wainwright raised their target price on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Canaccord Genuity Group dropped their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

Insider Transactions at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AngioDynamics

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in shares of AngioDynamics by 110.4% during the third quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock valued at $1,240,000 after purchasing an additional 83,622 shares in the last quarter. State Street Corp boosted its position in shares of AngioDynamics by 2.7% during the third quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock valued at $6,305,000 after purchasing an additional 21,218 shares in the last quarter. Barclays PLC boosted its position in shares of AngioDynamics by 81.0% during the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock valued at $651,000 after purchasing an additional 37,394 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after acquiring an additional 123,271 shares in the last quarter. Finally, CWM LLC boosted its holdings in AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after acquiring an additional 8,832 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.